Previous 10 | Next 10 |
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...
Lyra Therapeutics, Inc. (LYRA) Q1 2021 Earnings Conference Call May 11, 2021 04:30 PM ET Company Participants Stephen Jasper - Principal, Gilmartin Group Maria Palasis - President and Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Conference Call ...
Lyra Therapeutics (LYRA): Q1 GAAP EPS of -$0.60 misses by $0.12.Cash and cash equivalents of $66.1M.Press Release For further details see: Lyra Therapeutics EPS misses by $0.12
- Presented positive full data from LANTERN Phase 2 study of LYR-210 at COSM – - Appointed Robert Kern, MD, as Chief Medical Officer - - Conference call and webcast today at 4:30 p.m. ET - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics compa...
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the company wi...
Gainers: Sypris Solutions (SYPR) +75%.Ocugen (OCGN) +41%.Brooklyn ImmunoTherapeutics (BTX) +34%.MicroVision (MVIS) +32%.BioVie (BIVI) +29%.FreightCar America (RAIL) +27%.Uxin (UXIN) +26%.Birks Group (BGI) +24%.Meridian Bancorp (EBSB) +21%.22nd Century (XXII) +20%.Losers: I...
New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210...
- LYR-210 is Lyra’s lead product candidate for chronic rhinosinusitis - Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localize...
Lyra Therapeutics, Inc. (LYRA) Q4 2020 Earnings Conference Call March 09, 2021 04:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group Maria Palasis - President & Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Cori...
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
Lyra Therapeutics Inc. Website:
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...